ArticleBMC geriatrics2025
Prevalence of the QT interval prolongation and its risk factors in hospitalized geriatric patients: findings of a single center cross-sectional study in Pakistan.
Article in BMC geriatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- High-normal QT interval as a predictor of 1-year mortality in hospitalized older adults.Zeitschrift fur Gerontologie und Geriatrie · 2026Article
- Aging-Induced QT Prolongation as a Potential Contributor to Longevity.Journal of cardiovascular development and disease · 2026Review
- QT interval prolongation and heart failure severity: A longitudinal study.Bioinformation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesGeriatric inpatients are particularly susceptible to Torsades de Pointes (TdP) because they are usually polymorbid and often take QT-prolonging drugs. Since polypharmacy is common in hospitalized geriatrics, it may lead to QT-prolonging Drug-Drug interactions, resulting in adverse cardiac events. Additionally, a significant portion of geriatric patients likely have a combination of other risk factors such as heart failure, hypertension, left ventricular hypertrophy, myocardial infarction, ischemic heart disease, bradycardia, diabetes mellitus, and electrolyte imbalances. However, there is a lack of published data regarding the prevalence of risk factors for QT interval prolongation in this population. This study aimed to determine the prevalence of QT interval prolongation and its risk factors among hospitalized geriatric patients, shedding light on potential contributors to this life-threatening condition in a vulnerable population.
methodsThis cross-sectional study was conducted at Ayub Teaching Hospital, Abbottabad from December 17, 2023, to May 9, 2024. During this study, 384 patients aged 65 years and older were analyzed. Various QT-prolonging medications were assessed using the CredibleMeds® database, while drug-drug interactions were evaluated using the Lexicomp interactions database. Logistic regression was used to identify the predictors of QT interval prolongation.
resultsOur study found that QT prolongation was more common in females (50.8%) than in males (49.2%). Among these patients, 60.2% presented with six QT-prolonging risk factors. Overall, QT-prolonging drugs were prescribed to 99.5% of patients. A total of 970 QT-prolonging drugs were identified, with the majority (70.4%) carrying a conditional risk of Torsades de Pointes. The most frequently prescribed category of QT-prolonging drugs was diuretics, accounting for 228 instances. QT-prolonging Drug-Drug Interactions were identified in 23.2% of patients. Statistically significant differences were found between the two groups (Prolonged QT interval vs. normal QT interval) in various factors such as all DDIs (p = 0.008), triglycerides (p = 0.03), ischemic heart disease (p = 0.02), myocardial infarction (p = 0.01), antimicrobials (p = 0.004), anti-emetics (p = 0.01), and analgesics (p = 0.05). Univariate analysis showed a statistically significant association of QT interval prolongation with 6–10 DDIs (p = 0.03); 11–15 DDIs (p = 0.001), > 15 DDIs (p = 0.01), ischemic heart disease (p = 0.02), myocardial infarction (p = 0.01), antimicrobials (p = 0.04), and antiemetic’s (p = 0.01). In multivariate analysis, a statistically significant association of QT interval prolongation was found with 11–15 DDIs (p = 0.03).
conclusionThis study identified a high prevalence of various risk factors for QT interval prolongation. When prescribing medications to this patient population, clinicians should conduct comprehensive medication reviews, regularly monitor the QT interval, and consider alternative therapies. Educating patients on medication risks and adherence to monitoring is crucial for early detection and reporting of adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.